May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Twelve–month visual acuity outcomes after posterior subtenon triamcinolone acetonide injections for diabetic macular edema.
Author Affiliations & Notes
  • S.J. Bakri
    Cole Eye Institute – Cleveland Clinic Foundation, Cleveland, OH
  • P.K. Kaiser
    Cole Eye Institute – Cleveland Clinic Foundation, Cleveland, OH
  • L.E. Lerner
    Cole Eye Institute – Cleveland Clinic Foundation, Cleveland, OH
  • Footnotes
    Commercial Relationships  S.J. Bakri, None; P.K. Kaiser, None; L.E. Lerner, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3464. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.J. Bakri, P.K. Kaiser, L.E. Lerner; Twelve–month visual acuity outcomes after posterior subtenon triamcinolone acetonide injections for diabetic macular edema. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3464.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To assess visual acuity outcomes after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema (DME). Methods: Using a computer search, patients seen at the Cleveland Clinic between January 1999 and September 2003 with ICD–9 codes 362.53 and 362.83, treated with a posterior subtenon triamcinolone injection, were identified. Visual acuities were recorded from the charts at 1 month, 3 months, 6 months and 12 months and converted into logMAR values for statistical analysis. Results: 73 posterior subtenon triamcinolone injections for DME were performed in 63 eyes of 50 patients. Mean visual acuity was 0.6 (20/80) at presentation (n=73), 0.4 (20/50) at 1 month (n=27), 0.51 (20/65) at 3 months (n=59), 0.53 (20/68) at 6 months (n=47) and 0.5 (20/63) at 12 months (n=28). Only the 1 month mean visual acuity was statistically significant from the initial visual acuity (p=0.0496, unpaired Student’s t–test). When visual outcomes of first posterior subtenon injections were analyzed separately (n=63 injections), only the 1 month mean visual acuity (0.44, 20/55), was statistically different from the initial mean visual acuity (0.64, 20/87) (p= 0.0281, n=50). Analysis of second posterior subtenon injections (n=10) revealed no statistically significant change in visual acuity between initial acuity and the subsequent time points. Conclusions: Visual acuities remained stable over a 12–month period after posterior subtenon triamcinolone injections for diabetic macular edema. There was a statistically significant improvement in visual acuity at 1 month. 12–month visual acuity outcomes after posterior subtenon triamcinolone for diabetic macular edema 

Keywords: diabetic retinopathy • macula/fovea • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×